TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9207282
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mL saline, intramuscular injection)
Study: 8272262
Drug: GM-1 ganglioside,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-1 ganglioside, administered intravenously at a dose of 100 mg, 6 days a week for 2 months
Study: 3619096
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus 1 ml normal saline (Group 1)
Study: 3619096
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus 0.2 mg epinephrine (Group 3)
Study: 3619096
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus 0.3 mg epinephrine (Group 4)
Study: 3619096
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus 0.4 mg epinephrine (Group 5)
Study: 3619096
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus 0.5 mg epinephrine (Group 6)
Study: 19117033
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (3 g/day) plus vitamin D (1 mg/day) (Group A, n=49)
Study: 19117033
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements (Group C, n=50)
Study: 17522475
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) low dose (50 mg/week)
Study: 17522475
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) medium dose (100 mg/week)
Study: 17522475
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) high dose (200 mg/week)
Study: 12193356
Drug: Thrombolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis treatment in a clinical trial
Study: 12193356
Drug: Thrombolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis treatment if shown effective
Study: 7973772
Drug: Cisplatin/5-fluorouracil/leucovorin (PFL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/5-fluorouracil/leucovorin (PFL) combination
Study: 7973772
Drug: Vinorelbine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine at 20 mg/m2/d
Study: 7973772
Drug: Vinorelbine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine at 25 mg/m2/d
Study: 2700878
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (O.C.)
Study: 21150602
Drug: Isolated limb
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated limb infusion (ILI) with melphalan and actinimycin D
Study: 19567091
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Study: 19567091
Drug: 7 ml
Normalized name: ethanol 7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Study: 19567091
Drug: 6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Study: 19567091
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Study: 16389160
Drug: Quinapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril plus Losartan (20 mg/day + 100 mg/day)
Study: 11070965
Drug: Preemptive intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive intravenous morphine (0.15 mg.kg‐1)
Study: 11070965
Drug: Preemptive epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive epidural morphine (75 micrograms.kg‐1)
Study: 11070965
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous saline)
Study: 9061114
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of vecuronium administered 5 minutes prior to inflation of a pneumatic tourniquet (Group I)
Study: 9061114
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of vecuronium administered after inflation of the tourniquet (Group II)
Study: 9061114
Drug: Neostigmine 30‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 30‐40 micrograms/kg i.v. administered to all subjects in both groups
Study: 8112641
Drug: Closure including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Closure including subcutaneous retention sutures
Study: 21349756
Drug: Pédimed(®) cream
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pédimed(®) cream applied twice daily for 4 weeks
Study: 21349756
Drug: Pédimed(®) cream
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pédimed(®) cream
Study: 15932664
Drug: Nadroparin (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (0.075 ml/10 kg)
Study: 12172535
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (2.4 million units, intramuscular injection)
Study: 10682964
Drug: Brinzolamide 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 1.0% twice daily
Study: 10682964
Drug: Brinzolamide 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 1.0% three times daily
Study: 9744373
Drug: Brinzolamide 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 1.0% (twice daily)
Study: 9744373
Drug: Brinzolamide 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 1.0% (three times daily)
Study: 7544184
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (before immunotherapy)
Study: 869668
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride (various doses)
Study: 26302034
Drug: Low-fat yoghurt
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat yoghurt supplemented with 80 mg d(‐1) of rooster comb extract (RCE)
Study: 16647404
Drug: Pamidronate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate therapy
Study: 10824468
Drug: Epsilon aminocaproic
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon aminocaproic acid (100 mg/kg body wt) intravenously slowly soon after anaesthetic induction, followed by 100 mg/kg in the cardiopulmonary bypass pump and 100 mg/kg after weaning from bypass over a period of 3 h
Study: 9035702
Drug: Once-daily treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily treatment of Tazarotene
Study: 1627203
Drug: Sertaconazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole 1% cream applied twice a day for 4 weeks
Study: 1627203
Drug: Sertaconazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole 2% cream applied twice a day for 4 weeks
Study: 6148959
Drug: Bisoprolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 40 mg
Study: 24925722
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system inhibitors (mostly but not entirely)
Study: 18039351
Drug: BAY 79‐4980
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 79‐4980 (13 or 22 mg kg(‐1) pegylated liposomes)
Study: 17665483
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg subcutaneously every other week for 24 weeks
Study: 7555033
Drug: 1 capsule
Normalized name: Cebocap 1 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule twice daily (A)
Study: 7555033
Drug: 2 capsules
Normalized name: Xymogen Berberine With Insea2 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules in the morning and 1 in the evening (B)
Study: 7555033
Drug: 2 capsules
Normalized name: Xymogen Berberine With Insea2 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules twice daily (C)
Study: 2258450
Drug: Amoxapine 400
Normalized name: Amoxapine
DrugBank: Amoxapine (DB00543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxapine 400 mg
Study: 2258450
Drug: Amitriptyline 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 300 mg
Study: 7008475
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (LDH)
Study: 31900193
Drug: Lottery prizes
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lottery prizes conditional on high adherence measured by a medication event management system (MEMS) cap (T2, n=110)
Study: 30539411
Drug: IMR-cCTA (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMR-cCTA (80 kV; automated-mAs; 60 mL of CM, 350 mgL/mL)
Study: 24350624
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with totally extraperitoneal endoscopic mesh placement
Study: 19920416
Drug: Mepivacaine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 400 mg diluted in 20 mL
Study: 19920416
Drug: Mepivacaine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 400 mg diluted in 30 mL
Study: 19920416
Drug: Mepivacaine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 400 mg diluted in 40 mL
Study: 14756642
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects of treatment
Study: 11708314
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement (10 g protein, 7 g carbohydrate, 3.3 g fat, and one-third of RDA of vitamins and minerals) ingested immediately after exercise.
Study: 11708314
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) did not ingest the protein supplement.
Study: 9514139
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg of AA, daily for the first week of life
Study: 3406600
Drug: Drugs or
Normalized name: herbal drugs ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs or relaxation therapy
Study: 31129371
Drug: Intensive Telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Telephone Counseling (ITC; eight proactive sessions/eight weeks of nicotine patches, plus discussion of the LCS results)
Study: 31129371
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care (UC; three proactive telephone counseling sessions/two weeks of nicotine patches)
Study: 26780271
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) adjunct to scaling and root planing (SRP)
Study: 26780271
Drug: Conventional non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-surgical periodontal therapy (NSPT)
Study: 24996197
Drug: Brivanib 800
Normalized name: Brivanib
DrugBank: Brivanib (DB11958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib 800 mg orally once-daily
Study: 22406155
Drug: Anti-TB drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TB drug treatment
Study: 19783386
Drug: Modafinil (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200, 400, or 600 mg)
Study: 17645384
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy plus cardiac rehabilitation
Study: 9051540
Drug: IV ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ondansetron 4 mg and saline
Study: 9051540
Drug: IV ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ondansetron 4 mg followed by IV dexamethasone 20 mg
Study: 3002987
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B polysaccharide and OMV vaccine
Study: 3403868
Drug: Theolan Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolan Suspension (administered every 12 hours)
Study: 3403868
Drug: Aminophylline solution
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline solution (administered every 8 hours)
Study: 3403868
Drug: Theolan Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolan Suspension
Study: 3403868
Drug: Aminophylline solution
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline solution
Study: 31915170
Drug: Personalised intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalised intervention including interactive responses and medication and follow-up reminders, in addition to usual care and general educational messages.
Study: 28011243
Drug: Drug-Eluting Balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Balloon (DEB)
Study: 26790201
Drug: Interactive dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive dynamic scalp acupuncture therapy
Study: 26790201
Drug: Traditional scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional scalp acupuncture therapy
Study: 21569309
Drug: Sertraline (titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (titration up to the minimum vs maximum of the recommended dose range)
Study: 21569309
Drug: Sertraline (staying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (staying on sertraline)
Study: 21569309
Drug: Sertraline (augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (augmentation with mirtazapine)
Study: 21569309
Drug: Mirtazapine (switching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (switching from sertraline to mirtazapine)
Study: 15605345
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy (PT) care
Study: 11370405
Drug: Drug information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug information from the pharmaceutical industry
Study: 24848990
Drug: Ibuprofen sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen sodium 400 mg
Study: 24848990
Drug: Ibuprofen-poloxamer 400
Normalized name: Poloxamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-poloxamer 400 mg
Study: 24128134
Drug: Sirolimus (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (initiated at 2 mg/d, adjusted to 6 to 8 ng/mL)
Study: 21403463
Drug: DTwP‐HBV+Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP‐HBV+Hib vaccine (SIIL)
Study: 21403463
Drug: TritanrixHB+Hiberix vaccine
Normalized name: Hiberix
DrugBank: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (DB10990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TritanrixHB+Hiberix vaccine (GSK)
Study: 21403463
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose for both SIIL and GSK groups
Study: 10879992
Drug: Cetirizine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine treatment for 6 weeks
Study: 10879992
Drug: Cetirizine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine treatment for 1 week
Study: 3535490
Drug: Oral milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral milrinone therapy (10 +/- 1 weeks)
Study: 3535490
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone after withdrawal of oral drug for 24 hours
Study: 3535490
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of oral milrinone
Study: 31338575
Drug: Antiadhesive agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiadhesive agent
Study: 31338575
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiadhesive agent)
Study: 24641978
Drug: Acute heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute heroin administration
Study: 22243563
Drug: THC (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (0.025 mg/kg)
Study: 16315875
Drug: Cimetidine administration
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine administration during chemotherapy
Study: 16315875
Drug: Non-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-administration of cimetidine during chemotherapy
Study: 11782685
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF (500 mg BID for 10 days)
Study: 11782685
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (250 mg BID for 10 days)
Study: 2563327
Drug: Home-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based treatment with massed exposure
Study: 2563327
Drug: Home-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based treatment with spaced exposure
Study: 2563327
Drug: Home-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based treatment with self-controlled exposure
Study: 2563327
Drug: Home-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based treatment with therapist-controlled exposure
Study: 31833974
Drug: Anti-HER2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-HER2 therapy
Study: 27682868
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives (£15 for each LAI medication)
Study: 9607059
Drug: Live human
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live human rotavirus vaccine 89-12 (10^5 p.f.u. dose-1)
Study: 11835845
Drug: Local homoharringtonine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local homoharringtonine and dexamethasone treatment
Study: 11835845
Drug: Local dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local dexamethasone treatment
Study: 11835845
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug treatment (untreated group)
Study: 15278645
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine solution (pH 7.12)
Study: 21459975
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy intervention (manual based developmental group therapy programme)
Study: 15639688
Drug: EZE/SIMVA (10/10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA (10/10, 10/20, 10/40, or 10/80 mg)
Study: 10667618
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/day, increased to 100 mg/day if necessary)
Study: 10667618
Drug: Moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300 mg/day, increased to 450 mg/day if necessary)
Study: 343748
Drug: Intraluminal fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraluminal fluorouracil (30 mg/kg) with intravenous fluorouracil (10 mg/kg) on the first two postoperative days and five subsequent courses of oral fluorouracil (90 mg/kg) over one year.
Study: 31264294
Drug: High-dose CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CBD co-administered with THC
Study: 30450532
Drug: Chemotherapy (paclitaxel/carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (paclitaxel/carboplatin with or without bevacizumab)
Study: 30450532
Drug: Leptin/adiponectin ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin/adiponectin ratio (L/A) before treatment
Study: 21688658
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia with paracetamol, lornoxicam, and epidural ropivacaine (Group 1)
Study: 21688658
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia with paracetamol, epidural ropivacaine, and tramadol (Group 2)
Study: 16430565
Drug: Gel lubrication
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel lubrication
Study: 16430565
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel lubrication (control)
Study: 11378806
Drug: High phenol
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High phenol diet (69 g per day of extra virgin olive oil rich in phenols)
Study: 11378806
Drug: Low phenol
Normalized name: yellow phenolphthalein
DrugBank: Phenolphthalein (DB04824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low phenol diet (69 g per day of extra virgin olive oil poor in phenols)
Study: 9463202
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 ml of 0.9% saline solution)
Study: 10442378
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and UFT plus oral calcium folinate
Study: 2198315
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg pefloxacin (PEFLO) once daily
Study: 2198315
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ofloxacin (OFLO) once daily